COHEN ALAIN J 4
4 · C4 Therapeutics, Inc. · Filed Oct 6, 2020
Insider Transaction Report
Form 4
COHEN ALAIN J
Director10% Owner
Transactions
- Conversion
Common Stock
2020-10-06+237,149→ 237,149 total(indirect: See Footnote) - Conversion
Common Stock
2020-10-06+2,484,425→ 2,484,425 total(indirect: By Cobro Ventures Opportunity Fund, L.P.) - Conversion
Series A Preferred Stock
2020-10-06−12,500,000→ 0 total(indirect: See Footnote)→ Common Stock (1,482,183 underlying) - Conversion
Common Stock
2020-10-06+1,482,183→ 1,719,332 total(indirect: See Footnote) - Conversion
Series Seed Preferred Stock
2020-10-06−2,000,000→ 0 total(indirect: See Footnote)→ Common Stock (237,149 underlying) - Conversion
Series B Preferred Stock
2020-10-06−20,952,403→ 0 total(indirect: By Cobro Ventures Opportunity Fund, L.P.)→ Common Stock (2,484,425 underlying)
Footnotes (3)
- [F1]Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.
- [F2]Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- [F3]Shares held by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures"). The Reporting Person serves as a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures, and may be deemed to exercise voting and investment power over the shares held by Cobro Ventures. The Reporting Person disclaims beneficial ownership of the shares held by Cobro Ventures except to the extent of his pecuniary interest therein.